



# NAD<sup>+</sup>: Scientific Evidence and Medical Applications

Authors: Monis, A. and Maple, K.

Date: September 2024

## Abstract

NAD<sup>+</sup> (nicotinamide adenine dinucleotide) has emerged as a critical coenzyme in cellular metabolism, energy homeostasis, and disease prevention. As a pivotal molecule found in every living cell, NAD<sup>+</sup> is necessary for a multitude of biological processes such as DNA repair, cellular signaling, and the regulation of circadian rhythm. Recent studies have highlighted the potential therapeutic benefits of NAD<sup>+</sup> and its role in supporting cellular health and longevity. Evidence suggests that increasing NAD<sup>+</sup> levels in the body may offer regenerative properties, particularly by enhancing mitochondria function, which is crucial for maintaining optimal cellular energy levels and reducing oxidative stress.

This white paper provides a comprehensive overview of the current research on NAD<sup>+</sup> and its medical applications, focusing on its potential usage in treating neurodegenerative conditions, metabolic disorders, age-related diseases, and other chronic illnesses. By analyzing existing scientific evidence, this whitepaper aims to offer valuable insights into the therapeutic potential of NAD<sup>+</sup> and emphasize the need for future research in the development of targeted interventions that focus on its benefits for human health.

# Table of Contents

NAD+ Medical Evidence

Table of Contents

Introduction

Problem Statement

Literature Review

Methodology

Results/Findings

Discussion

Conclusion

References

Appendices

Acknowledgments

Conflicts of Interest

Contact Information

## Introduction

Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is a natural coenzyme that plays a crucial role in the human body at the cellular level. It was the first cofactor ever described, discovered in 1906 by British biochemists Arthur Harden and William John Young. Their research showed that adding boiled yeast extracts to non-boiled yeast extracts accelerated alcoholic fermentation, leading them to identify a factor that promoted the reaction, which they called cozymase. Two decades later, German-Swedish biochemist Hans von Euler-Chelpin determined that cozymase contained adenine. In 1936, German physiologist Otto Heinrich Warburg further advanced this discovery by revealing that cozymase (now NAD<sup>+</sup>) could transfer hydride between molecules, identifying nicotinamide as the site of redox reactions.

NAD<sup>+</sup> is present in every cell and exists not only in humans but also in animals and plants. It is essential for energy production and supports various cellular functions, including metabolic pathways, DNA repair, and other critical processes. Through both direct and indirect mechanisms, NAD<sup>+</sup> influences numerous cellular activities vital to maintaining overall health and function.

## Problem Statement

The significance of NAD<sup>+</sup> is well-recognized, particularly in relation to its natural decline with age. This decrease in NAD<sup>+</sup> levels has become a key focus in studies exploring anti-aging strategies, as it may be linked to an increased risk of age-related diseases. As a result, there is a growing interest in researching methods to naturally boost NAD<sup>+</sup> levels in the body, offering potential insights into improving longevity and reducing age-associated health risks.

## Literature Review

We considered studies by C. Canto, S. Amjad, N.J. Conlon, et al to provide a detailed overview of evidence surrounding the use of therapies to potentially increase NAD<sup>+</sup> levels. This whitepaper also analyzed studies and reviews carried out by Y. Zhao et al, S. Lautrup et al, Campbell, Ruskovska and Bernlohr, Y. Baichuan et al, Rappou et al, Chen et al, and Blum et al. These studies analyzed different aspects of NAD<sup>+</sup> ranging from its role in cognitive functioning to weight management, mental health, and substance use disorder.

The literature that we reviewed focused on more than identifying the role of increased NAD<sup>+</sup>, as several journal entries also provided more details on the effects that reduced levels of NAD<sup>+</sup> produce in the body.

## Methodology

The main goal of this white paper is to review evidence related to the function that NAD<sup>+</sup> plays in cellular functions and metabolism, as well as energy production. The studies included in this white paper also focus on the DNA-level impact that low NAD<sup>+</sup> may have and how restoring adequate levels of the coenzyme could affect patients.

## Results/Findings

C. Canto et al. provide a comprehensive summary of current evidence on NAD<sup>+</sup> metabolism, emphasizing its critical role in maintaining energy homeostasis and its connections to both the nucleus and mitochondria. The authors report that adaptive cellular metabolism relies heavily on NAD<sup>+</sup> to mediate energy signaling. NAD<sup>+</sup> also plays a key role in various health conditions, including metabolic syndrome, cancer, and aging, suggesting that NAD<sup>+</sup> therapeutics may have significant potential in the treatment of a range of diseases.

The research highlights NAD<sup>+</sup>'s ability to lower cholesterol levels and improve lipid balance, referencing a clinical study by X. Li et al., which underscores the importance of niacin in regulating HDL cholesterol levels.

S. Amjad et al. further explain that NAD<sup>+</sup> depletion can lead to the development of numerous diseases, with a particular focus on the coenzyme's role in cellular stress responses. Low NAD<sup>+</sup> levels impair neuronal plasticity and hinder the body's ability to repair DNA. The study also suggests that restoring NAD<sup>+</sup> could correct redox imbalances in diabetes, where NAD<sup>+</sup>

depletion is linked to insulin resistance and type 2 diabetes. Additionally, NAD<sup>+</sup> has been proposed as a therapeutic approach for non-alcoholic fatty liver disease, kidney disease, and certain cancers.

N.J. Conlon provides an insightful overview of NAD<sup>+</sup> in the context of regenerative medicine, explaining its fundamental role in cellular metabolism. Conlon notes that declining NAD<sup>+</sup> levels contribute to aging, and replenishing these levels may help counter age-related degeneration.

Y. Zhao et al. found that NAD<sup>+</sup> ameliorates cognitive impairment and reduces neuroinflammation in chronic cerebral hypoperfusion (CCH) models, both in vivo and in vitro. The protective effects of NAD<sup>+</sup> were linked to improved mitochondrial function and reduced reactive oxygen species (ROS) production. Mechanistic analyses revealed that CCH-induced damage is associated with reduced gene expression of PGC-1 $\alpha$  (PPAR- $\gamma$  co-activator1 $\alpha$ ) and its transcription factor Sirt1, both of which were restored by NAD<sup>+</sup> treatment. The study also reported that NAD<sup>+</sup> offers neuroprotection by mitigating hypoxia-induced inflammation and mitochondrial damage.

S. Lautrup et al. explored the role of NAD<sup>+</sup> and its metabolites in neuron adaptation to physiological stressors and neurodegenerative diseases. Their review showed that NAD<sup>+</sup> depletion is observed in accelerated aging models such as *C. elegans* and mouse models of ataxia telangiectasia (AT), xeroderma pigmentosum group A (XPA), and Cockayne syndrome (CS). Augmenting NAD<sup>+</sup> levels improved both healthspan and lifespan in these models, restoring mitochondrial function and enhancing neuronal survival. The paper suggests that NAD<sup>+</sup> plays a crucial role in reducing DNA damage and promoting nuclear-mitochondrial communication via SIRT1 and PGC-1 $\alpha$ . Although further research is needed, the authors indicate that NAD<sup>+</sup> augmentation may offer therapeutic potential for Alzheimer's, Parkinson's, ALS, and Huntington's diseases.

J.M. Campbell also examined NAD<sup>+</sup> and its effects on cognitive health, finding a positive correlation between NAD<sup>+</sup> precursor supplementation and reduced cognitive decline. However, Campbell notes that most studies have been conducted in animal models, emphasizing the need for controlled clinical trials.

T. Ruskovska and D.A. Bernlohr reviewed NAD<sup>+</sup>'s role in metabolic regulation, particularly in adipose tissue. They found that increased NAD<sup>+</sup> levels may boost mitochondrial activity in adipose tissue and improve metabolic health. The review also highlighted the role of NAD<sup>+</sup> in activating sirtuins, which counteract the negative effects of overnutrition and physical inactivity.

Y. Baichuan et al. studied the effects of NAD<sup>+</sup> precursor supplementation on weight loss, adiponectin, and leptin. Their findings revealed that NAD<sup>+</sup> supplementation reduced BMI and increased adiponectin levels but had no effect on leptin or overall body weight, suggesting that NAD<sup>+</sup> contributes to weight management primarily through adiponectin regulation.

E. Rappou et al. conducted a controlled clinical trial comparing NAD<sup>+</sup>/SIRT pathway expressions in adipose tissue between obese and lean individuals. They found that NAD<sup>+</sup>

expression was reduced in obese participants, while calorie restriction increased NAD<sup>+</sup>/SIRT1 pathway activity and reduced oxidative stress. This indicates NAD<sup>+</sup>'s key role in metabolic health and its responsiveness to dietary habits.

D.T.L. Chen et al. investigated the genetic associations between NAD<sup>+</sup> homeostasis and mental health, providing the first evidence that genetic variations in NAD<sup>+</sup> metabolism could be linked to major depressive disorder (MDD). Their study identified SNPs in the ACMSD gene, an enzyme involved in tryptophan catabolism and NAD<sup>+</sup> biosynthesis, as being associated with MDD.

K. Blum et al. conducted a pilot study on the efficacy of NAD<sup>+</sup> infusions in treating substance use disorder (SUD). Their findings suggest that NAD<sup>+</sup> infusions may be beneficial for SUD treatment, though more research is needed to confirm these results.

In conclusion, these studies collectively underscore NAD<sup>+</sup>'s vital role in energy metabolism, cognitive health, and disease prevention. Although promising, much of the research is still in early stages, and more human trials are required to fully understand NAD<sup>+</sup>'s therapeutic potential in various fields, including neurodegeneration, metabolic health, mental health, and substance use disorders.

## Discussion

The research reviewed in this white paper provides compelling evidence of the critical role NAD<sup>+</sup> plays in the aging process. As the body ages, NAD<sup>+</sup> levels naturally decline, leading to mitochondrial dysfunction, reduced cellular energy, and diminished resilience under stressful conditions. These adverse effects at the cellular level contribute to overall poor functionality and increase the risk of developing age-related diseases.

Several clinical trials and research studies indicate that NAD<sup>+</sup> levels can be effectively restored through the use of precursors, which help to replenish the coenzyme in the body. While different NAD<sup>+</sup> precursors exist, offering varying degrees of efficacy, this white paper does not focus on comparing them directly. However, the research clearly supports the importance of increasing NAD<sup>+</sup> levels in regenerative medicine and anti-aging therapies, positioning it as a promising avenue for further study and potential clinical applications.

## Conclusion

NAD<sup>+</sup> plays a pivotal role in maintaining energy homeostasis and supporting mitochondrial function, both of which are essential for overall cellular health. As individuals age, research has shown that NAD<sup>+</sup> levels naturally decline, which impairs the body's ability to respond to cellular stress and diminishes its protective effects on DNA. This decline not only affects cellular energy production but also contributes to increased vulnerability to age-related conditions.

NAD<sup>+</sup> operates through multiple pathways, impacting a wide range of biological functions. Studies have demonstrated that maintaining optimal NAD<sup>+</sup> levels can lead to significant health benefits, including improved HDL cholesterol levels, better regulation of cellular energy balance, and enhanced metabolic processes. Conversely, when NAD<sup>+</sup> levels are too low, research has linked this deficiency to reductions in neuronal plasticity, which can negatively affect cognitive function and increase the risk of neurodegenerative diseases.

In addition to its roles in energy production and mitochondrial function, NAD<sup>+</sup> is involved in DNA repair processes and the regulation of immune responses. Its decline with age has been associated with conditions such as metabolic syndrome, cardiovascular disease, and cognitive decline. By restoring NAD<sup>+</sup> levels, it may be possible to not only improve these conditions, but also promote healthier aging by enhancing the body's ability to repair damaged cells, maintain metabolic efficiency, and protect against chronic diseases.

In conclusion, NAD<sup>+</sup> plays an essential role in numerous physiological processes, and its decline with age has far-reaching implications for cellular function and overall health. As research continues, the therapeutic potential of increasing NAD<sup>+</sup> levels, particularly through supplementation and regenerative medicine, holds promise for improving age-related health outcomes and preserving cellular vitality.

## References

- Katsyuba E, Auwerx J. Modulating NAD<sup>+</sup> metabolism, from bench to bedside. *EMBO J*. 2017;36(18):2670-2683. doi:10.15252/embj.201797135
- Cantó C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. *Cell Metab*. 2015 Jul 7;22(1):31-53. doi: 10.1016/j.cmet.2015.05.023. Epub 2015 Jun 25. PMID: 26118927; PMCID: PMC4487780.
- Li X, Millar JS, Brownell N, Briand F, Rader DJ. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. *Biochem Pharmacol*. 2010 Nov 1;80(9):1450-7. doi: 10.1016/j.bcp.2010.07.023. Epub 2010 Jul 22. PMID: 20655299; PMCID: PMC3328801.
- Amjad S, Nisar S, Bhat AA, Shah AR, Frenneaux MP, Fakhro K, Haris M, Reddy R, Patay Z, Baur J, Bagga P. Role of NAD<sup>+</sup> in regulating cellular and metabolic signaling pathways. *Mol Metab*. 2021 Jul;49:101195. doi: 10.1016/j.molmet.2021.101195. Epub 2021 Feb 17. PMID: 33609766; PMCID: PMC7973386.
- Conlon NJ. The Role of NAD<sup>+</sup> in Regenerative Medicine. *Plast Reconstr Surg*. 2022 Oct 1;150(4 Suppl ):41S-48S. doi: 10.1097/PRS.0000000000009673. Epub 2021 Sep 28. PMID: 36170435; PMCID: PMC9512238.
- Zhao Y, Zhang J, Zheng Y, et al. NAD<sup>+</sup> improves cognitive function and reduces neuroinflammation by ameliorating mitochondrial damage and decreasing ROS production in

chronic cerebral hypoperfusion models through Sirt1/PGC-1 $\alpha$  pathway. *J Neuroinflammation*. 2021;18(1):207. Published 2021 Sep 16. doi:10.1186/s12974-021-02250-8

Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD<sup>+</sup> in Brain Aging and Neurodegenerative Disorders. *Cell Metab*. 2019;30(4):630-655. doi:10.1016/j.cmet.2019.09.001

Campbell JM. Supplementation with NAD<sup>+</sup> and Its Precursors to Prevent Cognitive Decline across Disease Contexts. *Nutrients*. 2022;14(15):3231. Published 2022 Aug 7. doi:10.3390/nu14153231

Ruskovska T, Bernlohr DA. The Role of NAD<sup>+</sup> in Metabolic Regulation of Adipose Tissue: Implications for Obesity-Induced Insulin Resistance. *Biomedicines*. 2023;11(9):2560. Published 2023 Sep 18. doi:10.3390/biomedicines11092560

Baichuan Y, Gomes Reis M, Tavakoli S, Khodadadi N, Sohoulí MH, Sernizon Guimarães N. The effects of NAD<sup>+</sup> precursor (nicotinic acid and nicotinamide) supplementation on weight loss and related hormones: a systematic review and meta-regression analysis of randomized controlled trials. *Front Nutr*. 2023;10:1208734. Published 2023 Oct 3. doi:10.3389/fnut.2023.1208734


Rappou E, Jukarainen S, Rinnankoski-Tuikka R, et al. Weight Loss Is Associated With Increased NAD(+)/SIRT1 Expression But Reduced PARP Activity in White Adipose Tissue. *J Clin Endocrinol Metab*. 2016;101(3):1263-1273. doi:10.1210/jc.2015-3054

Chen DT, Cheng SW, Chen T, et al. Identification of Genetic Variations in the NAD-Related Pathways for Patients with Major Depressive Disorder: A Case-Control Study in Taiwan. *J Clin Med*. 2022;11(13):3622. Published 2022 Jun 23. doi:10.3390/jcm11133622


Blum K, Han D, Baron D, et al. Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequelae in Substance Use Disorder (SUD) in Fifty Cases. *Curr Psychiatry Res Rev*. 2022;18(2):125-143. doi:10.2174/2666082218666220527114427

# Appendices

A




B



The reciprocal relationship between SIRT1 and PARPs during NAD<sup>+</sup> homeostasis and metabolic signaling in the cell

Cantó, C., Menzies, K., & Auwerx, J. (2015). NAD<sup>+</sup> metabolism and the control of energy homeostasis - a balancing act between mitochondria and the nucleus. *Cell Metabolism*, 22(1), 31. <https://doi.org/10.1016/j.cmet.2015.05.023>





Summary of the evidence for impaired NAD<sup>+</sup> metabolism in dysfunctional adipose tissue. Ruskovska T, Bernlohr DA. The Role of NAD<sup>+</sup> in Metabolic Regulation of Adipose Tissue: Implications for Obesity-Induced Insulin Resistance. *Biomedicines*. 2023;11(9):2560. Published 2023 Sep 18. doi:10.3390/biomedicines11092560

## Acknowledgments

The authors of this whitepaper acknowledge C. Canto, . Li, S. Amjad, N.J. Conlon, et al, for the work they have put into previous research papers, summaries, and clinical reviews, that made it possible to conclude on the efficacy and safety profile of NAD<sup>+</sup>.

## Conflicts of Interest

At the time of creating this whitepaper, the authors did not note any conflicts of interest.

## Contact Information

Please contact the authors directly if you have any queries about this whitepaper.